GlassScriptPhysician profile
Nikeyia Davis
NPI 1386229565
$3,509.33
in general payments reported to CMS, 2019-2025
18 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $539 · 2023: $843 · 2024: $471 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Charitable Contribution: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.57 |
| Charitable Contribution | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $650.79 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $600.00 | 2023 | |
| Fresenius USA Marketing, INC. | $390.30 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Vifor Pharma, INC. | $255.07 | 2022 | |
| Akebia Therapeutics INC | $245.89 | 2025 | Vafseo |
| Novo Nordisk INC | $241.88 | 2025 | Ozempic |
| Medtronic, INC. | $134.53 | 2025 | Symplicity G3 |
| Genzyme Corporation | $126.00 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $123.08 | 2021 | |
| Gilead Sciences, INC. | $121.85 | 2025 | Epclusa |
| Glaxosmithkline, LLC. | $121.36 | 2022 | |
| Cormedix INC. | $118.49 | 2024-2025 | Defencath, Defencath |
| Idorsia Pharmaceuticals US INC | $115.42 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.73 | 2023 | |
| Coloplast Corp | $70.76 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.22 | 2025 | Krystexxa |
| Lexicon Pharmaceuticals, INC. | $17.70 | 2023 | Inpefa |
| Bard Peripheral Vascular, INC. | $16.26 | 2024 | Pristine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikeyia Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.